中国科学院天津工业生物所 . 工业生物技术科学传播，天津工业生物所新闻动态 以下文章来源于中国科学院天津工业生物所 ，作者TIBCAS /生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ SynBio团队 | 天津工生所吴信研究员团队 作为植物细胞壁的主要组分之一，木质素是自然界中储量最丰富的可再生芳香族聚合物，每年全球农 林废弃物和造纸工业副产木质素总量超过 5000 万吨，但是由于其复杂的三维网状结构和顽固的化 学性质，木质素的生物高效降解与转化一直是工业生物技术领域的重大挑战。当前，利用微生物将木 质素转化为油脂和单细胞蛋白等高附加值产品仍存在降解酶系效率低、优良菌株选育周期长、细胞内 碳流定向调控难等多重瓶颈。 【SynBioCon】 获 悉 ， 近日， 中国科学院天津工业生物技术研究所吴信研究员 带领的营养资源 生物合成团队在木质素生物合成微生物油脂和蛋白取得突破性进展。 该团队创新性地将基因组碱基 编辑技术与液滴微流控超高通量筛选策略相结合，成功构建出具有高效木质素降解、油脂与蛋白同步 合成的棒状弯孢霉 Curvularia clavata 工程菌株 ...

Core Viewpoint - The document outlines the legal opinions and supplementary legal advice provided by King & Wood Mallesons regarding Blue Star Adisseo Co., Ltd.'s issuance of A-shares to specific targets, emphasizing compliance with Chinese laws and regulations [1][2][3]. Group 1: Issuance Details - The issuance includes projects such as a 150,000 tons/year solid methionine project and a 37,000 tons/year specialty feed additive project, among others [4][5]. - The company has not yet obtained the necessary overseas investment filing for the Burgos specialty feed additive project [4][5]. Group 2: Legal Compliance - The law firm confirms that it only provides opinions on Chinese legal matters and does not assess non-legal professional matters such as finance or accounting [3][4]. - The supplementary legal opinion is an integral part of the previously issued legal documents and maintains the same assumptions and premises [2][4]. Group 3: Overseas Investment - The overseas investment project is to be implemented by the company's subsidiary in Spain, focusing on specialty feed additives [7][8]. - The company has submitted the necessary overseas investment filing to the Ministry of Commerce, and there are no significant legal uncertainties expected regarding this process [10][12]. Group 4: Financial Assistance - The company has provided financial assistance to its joint venture, Calysseo, to support the construction of a facility for producing single-cell protein, which is strategically aligned with its core business [15][16]. - The financial assistance provided does not constitute a related party transaction under the Shanghai Stock Exchange rules [17][18].

Core Viewpoint - The company, Andisu, is undergoing significant capital operations, marking its largest since its reverse merger in 2015, with a focus on expanding its production capacity in the animal nutrition sector [1] Group 1: Company Overview - Andisu specializes in the research, production, and sales of animal nutrition additives, holding a leading position in the industry for several core products [3] - The company's product offerings are categorized into functional products, such as methionine and vitamins, and specialty products aimed at enhancing animal health and feed efficiency [3] Group 2: Investment Projects - The company plans to invest CNY 1.743 billion (approximately USD 246 million) in a solid methionine project with an annual capacity of 150,000 tons, accounting for 46.3% of the total fundraising amount [4] - The project will be located in Quanzhou, Fujian Province, and is expected to commence production in 2027 [4] - The liquid methionine production capacity at Andisu's Nanjing plant is currently the second largest globally, which will create synergies with the new solid methionine expansion [4] Group 3: Financial Performance - In 2024, Andisu is projected to achieve a revenue of CNY 15.53 billion (approximately USD 2.23 billion), representing a year-on-year growth of 17.83% [9] - The net profit attributable to shareholders is expected to reach CNY 1.204 billion (approximately USD 171 million), showing a dramatic increase of 2215% compared to 2023, although this is largely due to a low base effect from the previous year [9] - The company's net profit in 2023 was only CNY 52 million (approximately USD 7.4 million), a decline of nearly 96% from CNY 1.247 billion (approximately USD 178 million) in 2022 [9] Group 4: Market Dynamics - The methionine market is dominated by international giants, with a global market size projected to exceed 1.5 million tons by 2028, while the current domestic production rate is below 30% [3] - The industry has experienced a cyclical nature, with methionine prices significantly influenced by global capacity expansions, leading to an oversupply situation [10] - From 2016 to 2023, the average price of methionine in the domestic market decreased by 34% [10] Group 5: Cost and Profitability - The company's operating costs have risen sharply from CNY 7.465 billion (approximately USD 1.06 billion) in 2016 to CNY 13.669 billion (approximately USD 1.96 billion) in 2024 [12] - Despite efforts to optimize supply chain management, the pressure from rising costs, driven by high prices of key raw materials and global supply chain disruptions, has significantly impacted profitability [12] - The gross margin has decreased from 47.43% in 2016 to 21.38% in 2023, with a recovery to 30.21% anticipated in 2024 [10]